Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, First-In-Human, Multiple Phase, Single and Multiple-Ascending Dose Study of TERN-201 in Healthy Human Participants

Trial Profile

A Phase I, First-In-Human, Multiple Phase, Single and Multiple-Ascending Dose Study of TERN-201 in Healthy Human Participants

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TERN 201 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions; First in man
  • Sponsors Terns Pharmaceuticals
  • Most Recent Events

    • 13 Aug 2019 According to a Terns Pharmaceuticals media release, based on the interim results, the study has progressed to the multiple-dose phase.
    • 13 Aug 2019 According to a Terns Pharmaceuticals media release, the company look forward to seeing further results from this study later in the year.
    • 13 Aug 2019 Status changed from planning to recruiting, according to a Terns Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top